Skip to main content

Table 1 Characteristics of the 115 patients included in the AMA-AC program

From: Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy

Patient characteristics at diagnosis/entry to AMA-AC

(n = 115)

Gender Men (n;%)

64 (55.7 %)

Age (years)

 Mean (Min; Max)

55.0 (22.0; 87.0)

 Median

58

Health insurance (n;%)

 General health system

104 (90.4 %)

 Others (Agriculture, freelancers)

11 (9.6 %)

Cohabiting status (n;%)

 Living together (married, living in partnership)

87 (75.6 %)

 Living alone (single, divorced, widowed)

28 (24.4 %)

Level of education (n;%)

 Lower educational status (≤high school degree)

64 (55.7 %)

 Higher educational status (>high school degree)

51 (44.4 %)

Occupational status (n;%)

 In activity (employed)

61 (53.0 %)

 Without activity (without employment, retired, unemployed)

54 (47.0 %)

Salary net/month (n;%) (n = 86)

 No salary

3 (3.5 %)

<380€ - 1070€

20 (23.3 %)

>1070€ - 1830€

24 (27.9 %)

>1830€ - 2290€

12 (14.0 %)

>2290€ - 4570€

27 (31.4 %)

Disease-related characteristics

Histology (n;%)

 Diffuse large B-cell lymphoma (DLBCL)

64 (55.7 %)

 Other NHL

33 (28.6 %)

 Hodgkin lymphoma

18 (15.7 %)

Ann Arbor stage (n;%) (n = 112)

 I/ II

25 (22.3 %)

 III/ IV

87 (77.7 %)

Performance status (n;%)

  ≤ 1

96 (83.5 %)

  ≥ 2

19 (16.5 %)

Charlson comorbidity index (n;%)

 0

88 (76.5 %)

 1

9 (7.8 %)

  ≥ 2

18 (15.7 %)

Prognosis (according to IPI, FLIPI, IPS) (n = 112)

 Good

19 (16.52 %)

 Medium

59 (51.30 %)

 Bad

24 (20.87 %)

Treatment-related characteristics

Type of treatment line (n;%)a

 Conventional

84 (73.0 %)

 Intensified

31 (27.0 %)

  1. Abbreviations: IPI International Prognostic Index; FLIPI Follicular Lymphoma International Prognostic Index; IPS International Prognostic Score (Hasenclever Index)
  2. aType of treatment line: Conventional: CHOP21: 4 (3.5 %), R-CHOP21: 65 (56.5 %), R-mini-CHOP: 3 (2.6 %), ABVD: 12 (10.4 %); Intensified: R-ACVBP: 24 (20.9 %), R-COPADM: 1 (0.9 %), BEACOPP: 6 (5.2 %)